Acute B lymphoblastic leukemia (ALL)
Conditions
Interventions
treatment:treatment with Blinatumomab
Sponsors
Shenzhen Second People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: ?Aged 18 to 65 years old, male or female; ?Patients with minimal residual disease (MRD) after induction or consolidation or intensive therapy, MRD monitoring was routinely performed by flow cytometry; If BCR::ABL fusion gene was positive, real-time quantitative PCR was used to detect MRD; clearly diagnosed relapsed or refractory according to Chinese guidelines for diagnosis and treatment of adult acute lymphoblastic leukemia (2021); ?Plan to receive allogeneic hematopoietic stem cell transplantation within 45 days; ?Voluntarily receive Blinatumomab treatment and paid for the drug; ?The physical state assessment (ECOG) score was 0-2; ?Patients provided written informed consent
Exclusion criteria
Exclusion criteria: ? Uncontrolled severe infection; ? known to be allergic to components of berintuzumab or its analogues; ? recurrent central nervous system leukemia; ? history of severe heart disease, severe liver and kidney dysfunction, and severe bleeding; ? unconscious or mentally ill or unable to operate with the diagnosis and treatment; ? pregnant or breastfeeding; ? considered ineligible for enrollment by investigators
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 2-year cumulative incidence of relapse after transplantation; | — |
Secondary
| Measure | Time frame |
|---|---|
| incidence of Grade ?-? acute graft-versus-host disease;incidence of chronic graft-versus-host disease;2-year survival after transplantation;2-year leukemia-free survival after transplantation; | — |
Countries
China
Contacts
Public ContactYang Sitian
Shenzhen Second People's Hospital
Outcome results
None listed